-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Palvella Therapeutics, Raises Price Target to $190

Benzinga·12/16/2025 14:47:39
Listen to the news
Truist Securities analyst Danielle Brill maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $105 to $190.